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was mild with absence of neutropenia-related complica-
tions. Grade 3 neutropenia was observed in 3.7% of pa-
tients and grade 3 and 4 anemia was observed in 5.6 and 
1.9% of patients, respectively.  Conclusion: The weekly 
administration of docetaxel is highly effi cient and safe 
as fi rst-line treatment for MBC and may serve as an im-
portant treatment option specifi cally in elderly patients 
and patients with a reduced performance status. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Docetaxel (Taxotere ® , Aventis, Bad Soden, Germany) 
is one of the most effective antitumor agents currently 
available for the treatment of metastatic breast cancer 
(MBC). When compared with the gold standard doxoru-
bicin, docetaxel showed a signifi cantly superior response 
rate (47.8 vs. 33.3%, p = 0.008) and a trend towards a 
prolonged time to tumor progression (26 vs. 21 weeks) 
 [1] . After failure of anthracycline-containing chemother-
apy, single-agent docetaxel has demonstrated superior 
results when compared with mitomycin/vinblastine [re-
sponse, time to progression (TTP), survival] or metho-
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 Abstract 
 Background: Docetaxel is one of the most effective anti-
tumor agents currently available for the treatment of 
metastatic breast cancer (MBC). This phase II multicenter 
study prospectively analyzed the effi cacy and toxicity of 
docetaxel given on a weekly schedule as fi rst-line treat-
ment of metastatic breast cancer.  Patients and Methods: 
All patients received docetaxel, 35 mg/m 2  weekly for 6 
weeks, followed by 2 weeks of rest. Subsequent cycles 
(3 weeks of treatment, 2 weeks of rest) were given until 
a maximum of 5 cycles or disease progression. Premed-
ication consisted of 8 mg dexamethasone intravenously 
30 min prior to the infusion of docetaxel.  Results: Fifty-
four patients at a median age of 58 years with previous-
ly untreated MBC were included in the study. A median 
of 10 doses (median cumulative dose 339 mg/m 2 ) was 
administered (range: 2–18). The overall response rate 
was 48.1% (95% CI: 34–61%, intent-to-treat). Median sur-
vival was 15.8 months and median time to progression 
was 5.9 months (intent-to-treat). Hematological toxicity 
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trexate/5-fl uorouracil (response, TTP)  [2, 3] , and has 
shown equivalent effi cacy when compared with vinorel-
bine/5-fl uorouracil (response, TTP, survival)  [4] . 
 The major rationale of a weekly schedule is the marked 
reduction of hematological toxicity  [5–8] . When docetax-
el is administered at a dose of 100 mg/m 2  every 3 weeks, 
70–90% of patients develop grade 3/4 neutropenia. In 
previously reported phase II studies, severe (grade 3/4) 
hematological toxicity was uncommon at doses less than 
40 mg/m 2  given on a weekly basis  [5–8] . The response 
rate achieved in these studies for pretreated patients 
ranged from 25 up to 41%  [5–8] . 
 An additional rationale for weekly docetaxel might be 
an equivalent dose intensity of treatment compared with 
the 3-weekly administration of docetaxel at a standard 
dose of 100 mg/m 2 . However, in pretreated and elderly 
patients, the 3-weekly dose of 100 mg/m 2  frequently 
needs to be adjusted to 75 mg/m 2   [9, 10] . Given the im-
proved tolerability of the weekly schedule, an increase of 
dose intensity may be achieved specifi cally in these pa-
tients  [5–8] . 
 While numerous studies have evaluated the weekly ap-
plication of docetaxel in pretreated patients, this is the 
fi rst report to analyze the effi cacy and toxicity of weekly 
docetaxel in fi rst-line therapy of MBC. 
 Patients and Methods 
 Patient Selection 
 Fifty-four patients with MBC were recruited. None of the pa-
tients had received chemotherapy for metastatic disease. The treat-
ment protocol was approved by the local ethics committee and all 
patients gave written informed consent before treatment was
started. 
 Patients were required to have histologically proven MBC, bi-
dimensionally measurable disease, a WHO performance status of 
0–2, be aged between 18 and 70 years, and have an anticipated 
survival of at least 12 weeks. Cardiac, hepatic, renal and hemato-
logical function had to be adequate [leukocyte count  6 3.0  ! 
10 9 /l; platelets  6 100  ! 10 9 /l; hemoglobin  6 8 g/dl; bilirubin 
 ^  1.25  ! normal range; ALT:AST (alanine aminotransferase:as-
partate aminotransferase) ratio  ^  3  ! normal range; alkaline phos-
phatase  ^  2.5  ! normal range].  Patients with only bone metastases 
were not eligible for the trial. Additional exclusion criteria were 
radiotherapy of more than 25% of marrow-containing bone, brain 
metastases, previous neuropathy  6 grade 2, and a history of a sec-
ond malignancy other than resected basal cell and/or squamous cell 
carcinoma of the skin. 
 Treatment Regimen 
 Patients were treated with a weekly dose of 35 mg/m 2  docetax-
el for 6 weeks, followed by 2 weeks of rest. Further treatment cycles 
were performed with a modifi ed schedule, where docetaxel was ad-
ministered on days 1, 8 and 15 every 29 days (cycle 2 started on 
day 50). Docetaxel (35 mg/m 2  in 100 ml 0.9% NaCl) was given by 
intravenous (i.v.) infusion over 30 min. Premedication consisted 
of 8 mg dexamethasone given i.v. 30 min before the start of docetax-
el infusion. 
 Treatment was continued until either progression of disease, 
demonstration of severe side effects, or up to a maximum of 18 
single doses of docetaxel (5 cycles). 
 In case of myelosuppression (leukocyte count  ^  3,000/  l, plate-
let count  ^  100,000/  l) on the day of planned treatment, further 
drug administration was postponed for 1 week until bone marrow 
recovery occurred. A full dose of docetaxel was administered if the 
blood counts had risen to leukocytes  6 3,000/  l and platelets 
 6 100,000/  l. Dose reductions for toxicity were 30 mg/m 2  (level 
–1) and 25 mg/m 2  (level –2). The dose was reduced by one level for 
nonhematological toxicity  6 grade 3 (excluding alopecia and nau-
sea/vomiting) or hematological toxicity grade 3 or 4 complicated 
by fever or infection or both. There was a maximum of two dose 
reductions per patient. 
 Data Collection 
 Drug administration, performance status and toxicity or ad-
verse events were recorded after every cycle of docetaxel treatment. 
Weekly blood counts were performed. Febrile neutropenia was de-
fi ned as fever ( 6 38  °  C) with grade 4 neutropenia requiring i.v. an-
tibiotics and/or hospitalization without documented infection. Flu-
id retention included peripheral edema and/or pleural and pericar-
dial effusions. 
 Toxicity was graded according to the National Cancer Institute 
Common Toxicity Criteria  [11] . Imaging studies using ultrasonog-
raphy, computed tomography (CT), and magnetic resonance imag-
ing (MRI) were performed after every two cycles of docetaxel treat-
ment. 
 Response Evaluation 
 In all patients, tumors were measured by physical examination, 
imaging procedures such as CT or MRI within 14 days prior to en-
try into the study and subsequently after every two cycles of treat-
ment. Standard evaluation by history, physical examination and 
routine laboratory tests (including complete blood cell count, chem-
istry profi le and electrolyte determination) was performed before 
each treatment. 
 Patient response was assessed by standard WHO criteria, as fol-
lows complete response (CR) was defi ned as the disappearance of 
all known disease, as determined by two observations not less than 
4 weeks apart, while partial response (PR) was defi ned as a decrease 
by at least 50% of the sum of the products of the largest perpen-
dicular diameters of all measurable lesions, as determined by two 
observations not less than 4 weeks apart. Stable disease (SD), last-
ing for at least 6 weeks from the start of study (i.e. fi rst drug admin-
istration), was defi ned as  ! 50% decrease and  ! 25% increase in the 
sum of the products of the largest perpendicular diameters of all 
measurable lesions. Progressive disease (PD) was a  1 25% increase 
in the size of at least one bidimensionally or unidimensionally mea-
surable lesion, or the appearance of a new lesion. The occurrence 
of pleural effusion was considered to be a sign of progression if it 
could be substantiated by positive cytology. 
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 Survival and TTP 
 TTP was determined by the interval between the initiation of 
therapy and the fi rst date when disease progression was objectively 
documented. Overall survival was measured from the date of treat-
ment start to the date of death from any cause. All patients were 
included for the analysis of TTP and survival (intent-to-treat). 
 Statistical Methods 
 The primary study end point was response rate. Probability of 
survival and time to progression were estimated by Kaplan-Meier 
analysis, and confi dence intervals for response rates were calcu-
lated using methods for exact binominal confi dence intervals  [12, 
13] . 
 Results 
 Patient Characteristics  
 Patient characteristics are presented in table  1 . 
 Effi cacy 
 In an intent-to-treat analysis 6 CR (11.1%), 20 PR 
(37.0%), 15 SD (27.8%) and 10 PD (18.5%) were ob-
served. Three patients (5.6%) were not evaluable. The 
overall response rate was 48.1% (95% CI: 34–61%). 
Among 41 patients who had received adjuvant chemo-
therapy, there were 5 CR (12.2%), 16 PR (39.0%), 10 SD 
(24.4%) and 7 PD (17.1%). Three patients (7.3%) were 
not evaluable. The overall response rate in this subgroup 
was 51.2% (95% CI: 35–67%). The clinical benefi t rate, 
defi ned as patients who achieved a CR or PR and patients 
who achieved a stabilization of the disease (CR + PR + 
SD), amounts to 75.9% (95% CI: 64–88%). 
 The response data are presented in detail in table  2 . 
 Survival data were available for all patients with a me-
dian follow-up period of 16.2 months. The median TTP 
was 5.9 months and the median overall survival amounts 
to 15.8 months (fi g.  1 ,  2 ). 
Table 1. Patient characteristics
Characteristic Patients
Patients 54
Age, years
Median
Range
665 years
58
37–80
21
WHO performance status
Median
0
1
2
 1
18
22
14
Estrogen receptor status
Positive
Negative
Unknown
26
24
4
Measurable disease sites
Lung
Liver
Lymph nodes
Skin
Skeletal
10
28
15
4
16
Number of disease sites per patient
1
2
  63
21
23
10
Prior treatment
Adjuvant chemotherapy
Adjuvant chemotherapy (anthracyclines)
Adjuvant hormonal therapy
Radiation
Surgery
Biopsy only (initially metastatic disease)
41
26
28
28
49
5
Table 2. Effi cacy (intent-to-treat; n = 54)
Total, n PR, n SD, n PD, n Not
evaluable, n
OR
% 95% CI
All 54 20 15 10 3 48.1 34–61
Adjuvant chemotherapy1 41 16 10  7 3 51.2 35–67
Adjuvant chemotherapy including
anthracyclines1 26 11  4  6 1 57.7 37–78
1 Percentage values are calculated relative to size of evaluable patients of subgroup.
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Censored data
 Fig. 1. Survival (intent-to-treat; n = 54), median 15.8 months (range 0.3–17.1 months). 
Censored data
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 Fig. 2. TTP (intent-to-treat; n = 54), median 5.9 months (range 0.1–15.6 months). 
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 Toxicity 
 All investigated hematological and nonhematological 
toxicities are listed in table  3 . Only 3.7% of patients ex-
perienced severe neutropenia (grade 3) and no febrile 
neutropenia was observed. None of the patients required 
hematological growth factor support. Mild anemia was 
common (grade 1 and 2: 25.9 and 13% of patients), but 
severe anemia was rarely noted including grade 3 and 4 
anemia in 5.6 and 1.9% of patients. Severe thrombocyto-
penia was uncommon and was observed in only 1.9% of 
patients (grade 3). 
 Except fl uid retention symptoms (grade 2) and neuro-
toxicity (grade 1) there were no signifi cant differences re-
garding the toxicity profi le in younger patients ( ! 65 years) 
versus elderly patients (age  6 65 years).  
 A dose reduction of one dose level (30 mg/m 2 ) was 
necessary in 3.1% of all administered doses (n = 653), 
while a second reduction (25 mg/m 2 ) was required in only 
1.1%. Delayed applications of single doses were necessary 
in 8.4% (table  4 ). 
 Discussion 
 Docetaxel has shown high effi cacy in fi rst-line treat-
ment of MBC yielding response rates up to 54% (95% CI: 
37–71%) and 67.7% (95% CI: 49–83%) when adminis-
Table 3. Toxicity profi le of weekly administered docetaxel (per patient analysis, n = 54)
Toxicity Grade 1, % Grade 2, % Grade 3, % Grade 4, %
Hematological toxicity
Neutropenia 18.5 (12.1 vs. 9.5) 18.5 (12.1 vs. 9.5) 3.7 (6.1 vs. 0) –
Febrile neutropenia – – – –
Anemia 25.9 (24.2 vs. 28.6) 13 (12.1 vs. 14.3) 5.6 (6.1 vs. 4.8) 1.9 (3.0 vs. 0)
Thrombocytopenia 5.6 (6.1 vs. 4.8) 3.7 (6.1 vs. 0) 1.9 (3.0 vs. 0) –
Nonhematological toxicity
Alopecia (grade 0–2) 16.7 (18.2 vs. 14.3) 40.1 (45.0 vs. 33.3) – –
Asthenia 7.4 (6.1 vs. 9.5) 5.6 (3.0 vs. 9.5) 5.6 (9.1 vs. 0) –
Conjunctivitis/lacrimation 5.6 (3.0 vs. 9.5) 5.6 (6.1 vs. 4.8) – –
Diarrhea 9.3 (12.1 vs. 4.8) 3.7 (3.0 vs. 4.8) 3.7 (3.0 vs. 4.8) –
Fever 3.7 (3.0 vs. 4.8) 1.9 (3.0 vs. 0) – –
Fluid retention/edema/effusions – 13.0 (21.2 vs. 0)a 1.9 (3.0 vs. 0)b –
Infection (not neutropenia-related) 5.6 (6.1 vs. 4.8) – 3.7 (6.1 vs. 0) –
Mucositis 16.7 (18.2 vs. 14.3) – 3.7 (0 vs. 9.5) –
Nail disorders 5.6 (3.0 vs. 9.5) 5.6 (6.1 vs. 4.8) 1.9 (3.0 vs. 0) –
Nausea/vomiting 18.5 (12.1 vs. 28.6) 3.7 (3.0 vs. 4.8) 3.7 (6.1 vs. 0) –
Neurotoxicity 14.8 (24.2 vs. 0) 1.9 (3.0 vs. 0) – –
Nose bleeding 7.4 (9.1 vs. 4.8) – – –
Constipation 3.7 (3.0 vs. 4.8) – – –
Pain (cancer-related) 16.7 (21.2 vs. 9.5) 7.4 (9.1 vs. 4.8) 7.4 (9.1 vs. 4.8) –
Taste disturbance 3.7 (6.1 vs. 0) – – –
Values in parentheses represent toxicity profi le of younger patients (<65 years; n = 33) vs. elderly patients (665 years; n = 21); per-
centage values are calculated relative to the  size of patients of subgroup.
a Edema: n = 7.
b Cytological positive pleural effusion in 1 patient.
Table 4. Toxicity profi le of weekly administered docetaxel (653 
single doses)
Single doses
n %
Dose reduction 
Dose level –1 (30 mg/m2, weekly)
Dose level –2 (25 mg/m2, weekly)
20
7
3.1
1.1
Delayed doses 
Total
Due to cytopenia
For other reasons
55
41
14
8.4
6.3
2.1
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tered at a dose of 100 mg/m 2  every 3 weeks  [14–16] . In 
pretreated patients, docetaxel treatment resulted in re-
sponse rates of 48–55%  [1, 9, 10, 17] . When docetaxel was 
given after anthracycline failure, response rates of 30–
42% were achieved in two randomized trials  [2, 3] . 
 Although the 3-weekly regimen has proven a high lev-
el of antitumor activity, it is accompanied by consider-
able hematological toxicity. Grades 3–4 neutropenia was 
observed in up to 97% of patients  [1, 9, 10, 17] . Regard-
ing these side effects, a dose reduction of docetaxel was 
recommended specifi cally in elderly and unfi t patients  [9, 
10] . When docetaxel doses were reduced to 60–75 mg/m 2  
every 3 weeks, overall response rates of 33–35% were re-
ported in pretreated patients with a moderate reduction 
of hematological side effects  [10, 18, 19] . 
 The administration of docetaxel at a weekly dose of 
35–40 mg/m 2  combines the advantages of a preserved 
dose intensity with a markedly reduced hematological 
toxicity relative to standard 3-weekly regimens  [5–8] . The 
response rate achieved in phase II studies for pretreated 
patients ranged from 25 up to 41%  [5–8] . But until now, 
there are no data of weekly docetaxel given as fi rst-line 
treatment for MBC. In this trial of previously untreated 
patients for metastatic disease, docetaxel induced an 
overall response rate of 48.1% (95% CI: 34–61%). The 
clinical benefi t rate (CR + PR + SD) amounts to 75.9% 
(95% CI: 64–88%). A disease control was achieved in a 
limited time of cytotoxic treatment (median doses/pa-
tient = 10), supporting the high effi cacy of single-agent 
weekly docetaxel. In this trial, the median TTP was 5.9 
months (range: 0.1–15.6), which was within the range of 
that reported for every three-week regimen (3–9 months) 
 [14, 16, 17] . 
 The standard regimen is accompanied by severe neu-
tropenia in up to 97% leading to infections (including 
febrile neutropenia) in up to 26% of the patients. This 
potentially life-threatening toxicity may, however, be pre-
vented by the application of docetaxel at weekly doses 
below 40 mg/m 2   [5–8] . In fact, grade 3 and 4 hemato-
logical toxicity was reduced to 5% (grade 3) and 1% (grade 
4) of patients  [5–8] . In the present study, grade 3 and 4 
neutropenia was observed in 3.7 and 0% of patients. Neu-
Grade 3/4 toxicity
weekly regimen of
docetaxel 35 mg/m2
3-weekly regimen of docetaxel
100 mg/m2
this trial Chan 
et al. [1]
Nabholtz 
et al. [2]
Sjöström 
et al. [3]
Median cumulative dose, mg/m² 339 679 564 570
Hematological, % of patients
Neutropenia 3.7 93.5 93.1 77a
Anemia 7.5 4.4 n.a. 2
Thrombopenia 1.9 1.3 4.1 3
Febrile neutropenia 0 5.7 9 n.a.
Nonhematological, % of patients
Alopecia (grade 2) 40.1 n.a. n.a. 74
Asthenia 5.6 14.5 16 12
Conjunctivitis/lacrimation – n.a. n.a. –
Diarrhea 3.7 10.7 7.5 10
Fluid retention overall 1.9b 6.3b n.a. 3
Infection 3.7 2.5 11 26c
Mucositis/stomatitis 3.7 5 9 9
Nausea/vomiting 3.7 3.1 4.5/2.5 6
Neurotoxicity – 8d 5e 5
Skin/nail 0/1.9 1.9/n.a. 4/2.5 2/5
n.a. = Not available.
a Leukopenia; b edema and pleural effusion; c includes febrile infection; d neurosensory 
plus neuromotor; e neurosensory.
Table 5. Comparative analysis of
hematological and nonhematological
toxicity
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tropenic fever was not observed and none of the patients 
required G-CSF support. The low number of dose reduc-
tions [dose level –1 (30 mg/m 2 ): 3.1%; dose level –2
(25 mg/m 2 ): 1.1%] and treatment delays (8.4% of cycles) 
also refl ects the low hematological toxicity of this regi-
men. 
 Despite the marked difference in hematological toxic-
ity, nonhematological side effects were not signifi cantly 
different between the weekly and the 3-weekly schedule 
(table  5 ). The incidence of severe nonhematological tox-
icity was low. 
 Asthenia and fatigue were reported as the most com-
mon reason for dose reduction. In this study, grade 3 as-
thenia was reported only in 5.6% of patients. The lower 
weekly dose of 35 mg/m 2  chosen in this study compared 
to the dose of 40 mg/m 2  used by Burstein et al.  [5]  may 
explain the lower incidence of severe asthenia observed 
in this trial (table  5 ). 
 Conjunctivitis and lacrimation are also known sequel-
ae of docetaxel treatment  [20] . The incidence of 11.2% 
(grade 1 and 2 toxicity) in the present study is in good 
agreement with a previous report stating a 12% overall 
incidence in the 3-weekly regimen  [3] . Also mucositis, 
stomatitis, and nausea occurred at similar frequencies 
compared to the 3-weekly regimen. 
 Due to the low emetogenic potential of weekly doce-
taxel, 5-HT 3  antagonists were not required on a routine 
basis. 
 Severe fl uid retention symptoms occurred in 1.9% of 
patients (grade 3), which is in the range reported by other 
authors  [1, 3] . 
 To determine the toxicity profi le of weekly docetaxel 
in younger ( ! 65 years) and elderly patients ( 6 65 years) 
the incidence of side effects was presented for the whole 
study population and for each group separately (table  3 ) . 
 Except fl uid retention symptoms and neurotoxicity, there 
were no signifi cant differences regarding the toxicity pro-
fi le in younger and elderly patients, which supports the 
feasibility of weekly docetaxel even in the elderly pa-
tients. The signifi cantly increased incidence of fl uid re-
tention symptoms (grade 2) and neurotoxicity (grade 1) 
in the younger patients may be explained by the low num-
ber of patients in these subgroups. 
 This is the fi rst trial that evaluated a weekly adminis-
tration of docetaxel given as fi rst-line treatment for MBC. 
The weekly schedule induced a high level of activity and 
was well tolerated. Compared to a standard 3-weekly reg-
imen, the weekly regimen greatly reduced hematological 
toxicity. Specifi cally in elderly patients, where intensive 
chemotherapy is not feasible, a weekly administration of 
docetaxel may serve as an important treatment option. 
The limited duration of cytotoxic treatment in this trial 
(median 10 weeks) appears to be another argument for 
this schedule. Moreover, the short duration of drug ad-
ministration (30 min) clearly supports the use of this reg-
imen on an outpatient basis. Since conclusive data are 
missing, a randomized phase III study has been started 
to prospectively evaluate effi cacy and safety of a 3-week 
versus a weekly schedule in elderly patients. 
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